全文获取类型
收费全文 | 26290篇 |
免费 | 1636篇 |
国内免费 | 493篇 |
专业分类
耳鼻咽喉 | 175篇 |
儿科学 | 662篇 |
妇产科学 | 444篇 |
基础医学 | 1736篇 |
口腔科学 | 631篇 |
临床医学 | 5086篇 |
内科学 | 3156篇 |
皮肤病学 | 280篇 |
神经病学 | 1764篇 |
特种医学 | 1544篇 |
外国民族医学 | 1篇 |
外科学 | 3387篇 |
综合类 | 2039篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 3900篇 |
眼科学 | 215篇 |
药学 | 1619篇 |
5篇 | |
中国医学 | 336篇 |
肿瘤学 | 1436篇 |
出版年
2024年 | 55篇 |
2023年 | 717篇 |
2022年 | 1676篇 |
2021年 | 1961篇 |
2020年 | 1399篇 |
2019年 | 1354篇 |
2018年 | 844篇 |
2017年 | 1016篇 |
2016年 | 868篇 |
2015年 | 683篇 |
2014年 | 1353篇 |
2013年 | 1614篇 |
2012年 | 1286篇 |
2011年 | 1362篇 |
2010年 | 1028篇 |
2009年 | 1048篇 |
2008年 | 986篇 |
2007年 | 1078篇 |
2006年 | 908篇 |
2005年 | 908篇 |
2004年 | 789篇 |
2003年 | 761篇 |
2002年 | 587篇 |
2001年 | 475篇 |
2000年 | 371篇 |
1999年 | 346篇 |
1998年 | 311篇 |
1997年 | 241篇 |
1996年 | 195篇 |
1995年 | 220篇 |
1994年 | 213篇 |
1993年 | 179篇 |
1992年 | 211篇 |
1991年 | 181篇 |
1990年 | 132篇 |
1989年 | 129篇 |
1988年 | 125篇 |
1987年 | 92篇 |
1986年 | 81篇 |
1985年 | 123篇 |
1984年 | 84篇 |
1983年 | 66篇 |
1982年 | 69篇 |
1981年 | 63篇 |
1980年 | 52篇 |
1979年 | 35篇 |
1978年 | 48篇 |
1977年 | 34篇 |
1976年 | 16篇 |
1975年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
《Revista de gastroenterologia de Mexico》2022,87(1):52-58
IntroductionThe sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.MethodsA retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.ResultsOverall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported.ConclusionTreatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies. 相似文献
6.
7.
《Vaccine》2022,40(44):6431-6444
This is a Brighton Collaboration case definition of thrombosis and thromboembolism to be used in the evaluation of adverse events following immunization, and for epidemiologic studies for the assessment of background incidence or hypothesis testing. The case definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of SARS-CoV-2 vaccines. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected expert reviewers prior to submission. 相似文献
8.
9.
10.